People’s Republic of China

Weiyun Shi

Weiyun Shi is Director of Shandong Eye Institute and President of Shandong Eye Hospital. His research interests include infectious keratitis, corneal and cataract surgery. He serves as standing committee member of Chinese Ophthalmological Society, president of Chinese Cornea Society, and Associate Editor-in-Chief of the Chinese Journal of Ophthalmology. Professor Shi has received research grants from the National High Technology Research and Development Program of China and the National Natural Science Foundation of China. Moreover, he has not only published over 250 scientific papers, with more than 1,000 independent citations, but also authored the book of Surgery of the Cornea and co-authored the book of Cornea in China. Dr. Shi is an Expert Member of the Chinese Ophthalmological Society and an International Member of the American Academy of Ophthalmology. Among his honors are the Achievement Award of Asia-Pacific Academy of Ophthalmology and the Distinguished Award of Chinese Ophthalmological Society. Professor Shi also has several patents. Some of Prof. Shi’s notable patents include:  CTLA4 ophthalmic preparation; Long-acting cyclosporine intraocular drug delivery system; Mid-term corneal preservation solution; Intraocular implant for sustained drug release; Intraocular rapamycin delivery system with Bletilla striata gum as carrier; Sustained release carrier for ophthalmic medicine with synergistic treatment; Cationic adherence type amphotericin a nanoparticle eye drops; Cationic adhesion type mycophenolate mofetil nanoparticle eye drops; Preparation and application of human corneal endothelial cell culture media; Method for preparing limbal epithelial cell sheet with amnion membrane; and Cyclosporine A nanomicelles eye drops and preparation method.
< back

20 April

TFOS Guidelines

Ocular surface disease (OSD)—including dry eye disease, blepharitis, meibomian gland dysfunction, conjunctival inflammation, and cicatrizing ocular surface disorders—is one of the most common and underrecognized factors affecting the success of eye surgery (e.g., refractive, cataract, glaucoma, strabismus, retina, and oculoplastic). Conversely, optimizing the ocular surface is one of the most effective, modifiable strategies for enhancing surgical success across all ophthalmic subspecialties. And the central clinical principle appears to be universal: elective eye surgery...

17 April

EssilorLuxottica Partners with TFOS to Advance Ocular Surface Health Worldwide

TFOS is pleased to announce a new strategic partnership with EssilorLuxottica, a global leader in vision care and eyewear. This collaboration will support shared efforts to elevate awareness, education, and scientific progress in tear film and ocular surface health worldwide. By combining TFOS’s expertise in evidence-based consensus and professional education with EssilorLuxottica’s global reach and innovation capabilities, the partnership aims to help improve standards of care for patients affected by dry eye disease and related ocular surface conditions. Together, TFOS and EssilorLuxottica...

10 February

Latin American TFOS Ambassador Meeting

TFOS has organized a special meeting of the Latin American TFOS Ambassadors. This meeting, which will occur in Panama City this May, has two goals: first, to address the unmet needs for the management (e.g. diagnosis & treatment) of ocular surface diseases in their country/region, as well as what the Ambassadors perceive as short and long term scientific/clinical solutions; and second, to create a report for publication in a peer-reviewed journal. Participants will include TFOS Ambassadors from Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Ecuador, El Salvador, Guatemala, Honduras,...

Corporate Advisory Board Members